1
|
Botnariuc D, Court S, Lourenço A, Gosling A, Royle G, Hussein M, Rompokos V, Veiga C. Evaluation of monte carlo to support commissioning of the treatment planning system of new pencil beam scanning proton therapy facilities. Phys Med Biol 2024; 69:045027. [PMID: 38052092 DOI: 10.1088/1361-6560/ad1272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 12/05/2023] [Indexed: 12/07/2023]
Abstract
Objective. To demonstrate the potential of Monte Carlo (MC) to support the resource-intensive measurements that comprise the commissioning of the treatment planning system (TPS) of new proton therapy facilities.Approach. Beam models of a pencil beam scanning system (Varian ProBeam) were developed in GATE (v8.2), Eclipse proton convolution superposition algorithm (v16.1, Varian Medical Systems) and RayStation MC (v12.0.100.0, RaySearch Laboratories), using the beam commissioning data. All models were first benchmarked against the same commissioning data and validated on seven spread-out Bragg peak (SOBP) plans. Then, we explored the use of MC to optimise dose calculation parameters, fully understand the performance and limitations of TPS in homogeneous fields and support the development of patient-specific quality assurance (PSQA) processes. We compared the dose calculations of the TPSs against measurements (DDTPSvs.Meas.) or GATE (DDTPSvs.GATE) for an extensive set of plans of varying complexity. This included homogeneous plans with varying field-size, range, width, and range-shifters (RSs) (n= 46) and PSQA plans for different anatomical sites (n= 11).Main results. The three beam models showed good agreement against the commissioning data, and dose differences of 3.5% and 5% were found for SOBP plans without and with RSs, respectively. DDTPSvs.Meas.and DDTPSvs.GATEwere correlated in most scenarios. In homogeneous fields the Pearson's correlation coefficient was 0.92 and 0.68 for Eclipse and RayStation, respectively. The standard deviation of the differences between GATE and measurements (±0.5% for homogeneous and ±0.8% for PSQA plans) was applied as tolerance when comparing TPSs with GATE. 72% and 60% of the plans were within the GATE predicted dose difference for both TPSs, for homogeneous and PSQA cases, respectively.Significance. Developing and validating a MC beam model early on into the commissioning of new proton therapy facilities can support the validation of the TPS and facilitate comprehensive investigation of its capabilities and limitations.
Collapse
Affiliation(s)
- D Botnariuc
- Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London, WC1E 6BT, United Kingdom
- Metrology for Medical Physics Centre, National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, United Kingdom
| | - S Court
- Radiotherapy Physics Services, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, United Kingdom
| | - A Lourenço
- Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London, WC1E 6BT, United Kingdom
- Metrology for Medical Physics Centre, National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, United Kingdom
| | - A Gosling
- Radiotherapy Physics Services, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, United Kingdom
| | - G Royle
- Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London, WC1E 6BT, United Kingdom
| | - M Hussein
- Metrology for Medical Physics Centre, National Physical Laboratory, Hampton Road, Teddington, TW11 0LW, United Kingdom
| | - V Rompokos
- Radiotherapy Physics Services, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, United Kingdom
| | - C Veiga
- Department of Medical Physics and Biomedical Engineering, University College London, Gower Street, London, WC1E 6BT, United Kingdom
| |
Collapse
|
2
|
Tjelta J, Ytre-Hauge K, Lyngholm E, Handeland A, Henjum H, Stokkevåg C. Dose exposure to an adult present in the treatment room during pediatric pencil beam scanning proton therapy. Acta Oncol 2023; 62:1531-1535. [PMID: 37676843 DOI: 10.1080/0284186x.2023.2254924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Accepted: 08/29/2023] [Indexed: 09/09/2023]
Affiliation(s)
- Johannes Tjelta
- Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | | | - Erlend Lyngholm
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - Andreas Handeland
- Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - Helge Henjum
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - Camilla Stokkevåg
- Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| |
Collapse
|
3
|
Berrington de González A, Gibson TM, Lee C, Albert PS, Griffin KT, Kitahara CM, Liu D, Mille MM, Shin J, Bajaj BV, Flood TE, Gallotto SL, Paganetti H, Ahmed SK, Eaton BR, Indelicato DJ, Milgrom SA, Palmer JD, Baliga S, Poppe MM, Tsang DS, Wong K, Yock TI. The Pediatric Proton and Photon Therapy Comparison Cohort: Study Design for a Multicenter Retrospective Cohort to Investigate Subsequent Cancers After Pediatric Radiation Therapy. Adv Radiat Oncol 2023; 8:101273. [PMID: 38047226 PMCID: PMC10692298 DOI: 10.1016/j.adro.2023.101273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 05/08/2023] [Indexed: 12/05/2023] Open
Abstract
Purpose The physical properties of protons lower doses to surrounding normal tissues compared with photons, potentially reducing acute and long-term adverse effects, including subsequent cancers. The magnitude of benefit is uncertain, however, and currently based largely on modeling studies. Despite the paucity of directly comparative data, the number of proton centers and patients are expanding exponentially. Direct studies of the potential risks and benefits are needed in children, who have the highest risk of radiation-related subsequent cancers. The Pediatric Proton and Photon Therapy Comparison Cohort aims to meet this need. Methods and Materials We are developing a record-linkage cohort of 10,000 proton and 10,000 photon therapy patients treated from 2007 to 2022 in the United States and Canada for pediatric central nervous system tumors, sarcomas, Hodgkin lymphoma, or neuroblastoma, the pediatric tumors most frequently treated with protons. Exposure assessment will be based on state-of-the-art dosimetry facilitated by collection of electronic radiation records for all eligible patients. Subsequent cancers and mortality will be ascertained by linkage to state and provincial cancer registries in the United States and Canada, respectively. The primary analysis will examine subsequent cancer risk after proton therapy compared with photon therapy, adjusting for potential confounders and accounting for competing risks. Results For the primary aim comparing overall subsequent cancer rates between proton and photon therapy, we estimated that with 10,000 patients in each treatment group there would be 80% power to detect a relative risk of 0.8 assuming a cumulative incidence of subsequent cancers of 2.5% by 15 years after diagnosis. To date, 9 institutions have joined the cohort and initiated data collection; additional centers will be added in the coming year(s). Conclusions Our findings will affect clinical practice for pediatric patients with cancer by providing the first large-scale systematic comparison of the risk of subsequent cancers from proton compared with photon therapy.
Collapse
Affiliation(s)
| | - Todd M. Gibson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Choonsik Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Paul S. Albert
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Keith T. Griffin
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Cari Meinhold Kitahara
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Danping Liu
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Matthew M. Mille
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Jungwook Shin
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland
| | - Benjamin V.M. Bajaj
- Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Tristin E. Flood
- Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Sara L. Gallotto
- Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Harald Paganetti
- Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| | - Safia K. Ahmed
- Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
| | - Bree R. Eaton
- Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
| | - Daniel J. Indelicato
- Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida
| | - Sarah A. Milgrom
- Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado
| | - Joshua D. Palmer
- Department of Radiation Oncology, James Cancer Hospital at the Ohio State University Wexner Medical Center and Nationwide Children's Hospital, Columbus, Ohio
| | - Sujith Baliga
- Department of Radiation Oncology, James Cancer Hospital at the Ohio State University Wexner Medical Center and Nationwide Children's Hospital, Columbus, Ohio
| | - Matthew M. Poppe
- Department of Radiation Oncology, University of Utah–Huntsman Cancer Institute, Salt Lake City, Utah
| | - Derek S. Tsang
- Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
| | - Kenneth Wong
- Radiation Oncology Program, Children's Hospital Los Angeles, Los Angeles, California
- Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Torunn I. Yock
- Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
4
|
De Saint-Hubert M, Boissonnat G, Schneider U, Bäumer C, Verbeek N, Esser J, Wulff J, Stuckmann F, Suesselbeck F, Nabha R, Dabin J, Vasi F, Radonic S, Rodriguez M, Simon AC, Journy N, Timmermann B, Thierry-Chef I, Brualla L. Complete patient exposure during paediatric brain cancer treatment for photon and proton therapy techniques including imaging procedures. Front Oncol 2023; 13:1222800. [PMID: 37795436 PMCID: PMC10546320 DOI: 10.3389/fonc.2023.1222800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Accepted: 08/21/2023] [Indexed: 10/06/2023] Open
Abstract
Background In radiotherapy, especially when treating children, minimising exposure of healthy tissue can prevent the development of adverse outcomes, including second cancers. In this study we propose a validated Monte Carlo framework to evaluate the complete patient exposure during paediatric brain cancer treatment. Materials and methods Organ doses were calculated for treatment of a diffuse midline glioma (50.4 Gy with 1.8 Gy per fraction) on a 5-year-old anthropomorphic phantom with 3D-conformal radiotherapy, intensity modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT) and intensity modulated pencil beam scanning (PBS) proton therapy. Doses from computed tomography (CT) for planning and on-board imaging for positioning (kV-cone beam CT and X-ray imaging) accounted for the estimate of the exposure of the patient including imaging therapeutic dose. For dose calculations we used validated Monte Carlo-based tools (PRIMO, TOPAS, PENELOPE), while lifetime attributable risk (LAR) was estimated from dose-response relationships for cancer induction, proposed by Schneider et al. Results Out-of-field organ dose equivalent data of proton therapy are lower, with doses between 0.6 mSv (testes) and 120 mSv (thyroid), when compared to photon therapy revealing the highest out-of-field doses for IMRT ranging between 43 mSv (testes) and 575 mSv (thyroid). Dose delivered by CT ranged between 0.01 mSv (testes) and 72 mSv (scapula) while a single imaging positioning ranged between 2 μSv (testes) and 1.3 mSv (thyroid) for CBCT and 0.03 μSv (testes) and 48 μSv (scapula) for X-ray. Adding imaging dose from CT and daily CBCT to the therapeutic demonstrated an important contribution of imaging to the overall radiation burden in the course of treatment, which is subsequently used to predict the LAR, for selected organs. Conclusion The complete patient exposure during paediatric brain cancer treatment was estimated by combining the results from different Monte Carlo-based dosimetry tools, showing that proton therapy allows significant reduction of the out-of-field doses and secondary cancer risk in selected organs.
Collapse
Affiliation(s)
| | | | - Uwe Schneider
- Physik Institut, Universitat Zürich, Zürich, Switzerland
| | - Christian Bäumer
- West German Proton Therapy Centre Essen WPE, Essen, Germany
- West German Cancer Centre (WTZ), Essen, Germany
- Radiation Oncology and Imaging, German Cancer Consortium DKTK, Essen, Germany
- Department of Physics, TU Dortmund University, Dortmund, Germany
| | - Nico Verbeek
- West German Proton Therapy Centre Essen WPE, Essen, Germany
- West German Cancer Centre (WTZ), Essen, Germany
| | - Johannes Esser
- West German Proton Therapy Centre Essen WPE, Essen, Germany
- West German Cancer Centre (WTZ), Essen, Germany
- Faculty of Mathematics and Science Institute of Physics and Medical Physics, Heinrich-Heine University, Düsseldorf, Germany
| | - Jörg Wulff
- West German Proton Therapy Centre Essen WPE, Essen, Germany
- West German Cancer Centre (WTZ), Essen, Germany
| | - Florian Stuckmann
- West German Proton Therapy Centre Essen WPE, Essen, Germany
- West German Cancer Centre (WTZ), Essen, Germany
| | - Finja Suesselbeck
- West German Proton Therapy Centre Essen WPE, Essen, Germany
- West German Cancer Centre (WTZ), Essen, Germany
| | - Racell Nabha
- Belgian Nuclear Research Center (SCK CEN), Mol, Belgium
| | - Jérémie Dabin
- Belgian Nuclear Research Center (SCK CEN), Mol, Belgium
| | - Fabiano Vasi
- Physik Institut, Universitat Zürich, Zürich, Switzerland
| | | | - Miguel Rodriguez
- Hospital Paitilla, Panama City, Panama
- Instituto de Investigaciones Científicas y de Alta Tecnología INDICASAT-AIP, Panama City, Panama
| | | | - Neige Journy
- INSERM U1018, Paris Sud-Paris Saclay University, Villejuif, France
| | - Beate Timmermann
- West German Proton Therapy Centre Essen WPE, Essen, Germany
- West German Cancer Centre (WTZ), Essen, Germany
- Radiation Oncology and Imaging, German Cancer Consortium DKTK, Essen, Germany
- Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
- Department of Particle Therapy, University Hospital Essen, Essen, Germany
| | - Isabelle Thierry-Chef
- Barcelona Institute of Global Health (ISGlobal), Barcelona, Spain
- University Pompeu Fabra, Barcelona, Spain
- CIBER Epidemiología y Salud Pública, Madrid, Spain
| | - Lorenzo Brualla
- West German Proton Therapy Centre Essen WPE, Essen, Germany
- West German Cancer Centre (WTZ), Essen, Germany
- Radiation Oncology and Imaging, German Cancer Consortium DKTK, Essen, Germany
- Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
| |
Collapse
|
5
|
Griffin KT, Yeom YS, Mille MM, Lee C, Jung JW, Hertel NE, Lee C. Comparison of out-of-field normal tissue dose estimates for pencil beam scanning proton therapy: MCNP6, PHITS, and TOPAS. Biomed Phys Eng Express 2022; 9:10.1088/2057-1976/acaab1. [PMID: 36562506 PMCID: PMC10772933 DOI: 10.1088/2057-1976/acaab1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Accepted: 12/12/2022] [Indexed: 12/14/2022]
Abstract
Monte Carlo (MC) methods are considered the gold-standard approach to dose estimation for normal tissues outside the treatment field (out-of-field) in proton therapy. However, the physics of secondary particle production from high-energy protons are uncertain, particularly for secondary neutrons, due to challenges in performing accurate measurements. Instead, various physics models have been developed over the years to reenact these high-energy interactions based on theory. It should thus be acknowledged that MC users must currently accept some unknown uncertainties in out-of-field dose estimates. In the present study, we compared three MC codes (MCNP6, PHITS, and TOPAS) and their available physics models to investigate the variation in out-of-field normal tissue dosimetry for pencil beam scanning proton therapy patients. Total yield and double-differential (energy and angle) production of two major secondary particles, neutrons and gammas, were determined through irradiation of a water phantom at six proton energies (80, 90, 100, 110, 150, and 200 MeV). Out-of-field normal tissue doses were estimated for intracranial irradiations of 1-, 5-, and 15-year-old patients using whole-body computational phantoms. Notably, the total dose estimates for each out-of-field organ varied by approximately 25% across the three codes, independent of its distance from the treatment volume. Dose discrepancies amongst the codes were linked to the utilized physics model, which impacts the characteristics of the secondary radiation field. Using developer-recommended physics, TOPAS produced both the highest neutron and gamma doses to all out-of-field organs from all examined conditions; this was linked to its highest yields of secondary particles and second hardest energy spectra. Subsequent results when using other physics models found reduced yields and energies, resulting in lower dose estimates. Neutron dose estimates were the most impacted by physics model choice, and thus the variation in out-of-field dose estimates may be even larger than 25% when considering biological effectiveness.
Collapse
Affiliation(s)
- Keith T. Griffin
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
- George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA
| | - Yeon Soo Yeom
- Department of Radiation Convergence Engineering, Yonsei University, Wonju, South Korea
| | - Matthew M. Mille
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Choonik Lee
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
| | - Jae Won Jung
- Department of Physics, East Carolina University, Greenville, NC, USA
| | - Nolan E. Hertel
- George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA
| | - Choonsik Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| |
Collapse
|
6
|
Majer M, Ambrožová I, Davídková M, De Saint-Hubert M, Kasabašić M, Knežević Ž, Kopeć R, Krzempek D, Krzempek K, Miljanić S, Mojżeszek N, Veršić I, Stolarczyk L, Harrison RM, Olko P. Out-of-field doses in pediatric craniospinal irradiations with 3D-CRT, VMAT and scanning proton radiotherapy - a phantom study. Med Phys 2022; 49:2672-2683. [PMID: 35090187 DOI: 10.1002/mp.15493] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Revised: 12/01/2021] [Accepted: 01/12/2022] [Indexed: 11/08/2022] Open
Abstract
PURPOSE Craniospinal irradiation (CSI) has greatly increased survival rates for patients with a diagnosis of medulloblastoma and other primitive neuroectodermal tumors. However, as it includes exposure of a large volume of healthy tissue to unwanted doses, there is a strong concern about the complications of the treatment, especially for the children. To estimate the risk of second cancers and other unwanted effects, out-of-field dose assessment is necessary. The purpose of this study is to evaluate and compare out-of-field doses in pediatric CSI treatment using conventional and advanced photon radiotherapy (RT) and advanced proton therapy. To our knowledge, it is the first such comparison based on in-phantom measurements. Additionally, for out-of-field doses during photon RT in this and other studies, comparisons were made using analytical modeling. METHODS In order to describe the out-of-field doses absorbed in a pediatric patient during actual clinical treatment, an anthropomorphic phantom which mimics the 10-year-old child was used. Photon 3D-conformal radiotherapy (3D-CRT) and two advanced, highly conformal techniques: photon volumetric modulated arc therapy (VMAT) and active pencil beam scanning (PBS) proton radiotherapy were used for CSI treatment. Radiophotoluminescent (RPL) and poly-allyl-diglycol-carbonate (PADC) nuclear track detectors were used for photon and neutron dosimetry in the phantom, respectively. Out-of-field doses from neutrons were expressed in terms of dose equivalent. A two-Gaussian model was implemented for out-of-field doses during photon RT. RESULTS The mean VMAT photon doses per target dose to all organs in this study were under 50% of the target dose (i.e., <500 mGy/Gy), while the mean 3D-CRT photon dose to oesophagus, gall bladder and thyroid, exceeded that value. However, for 3D-CRT, better sparing was achieved for eyes and lungs. The mean PBS photon doses for all organs were up to 3 orders of magnitude lower compared to VMAT and 3D-CRT and exceeded 10 mGy/Gy only for the oesophagus, intestine and lungs. The mean neutron dose equivalent during PBS for 8 organs of interest (thyroid, breasts, lungs, liver, stomach, gall bladder, bladder, prostate) ranged from 1.2 mSv/Gy for bladder to 23.1 mSv/Gy for breasts. Comparison of out-of-field doses in this and other phantom studies found in the literature showed that a simple and fast two-Gaussian model for out-of-field doses as a function of distance from the field edge can be applied in a CSI using photon RT techniques. CONCLUSIONS PBS is the most promising technique for out-of-field dose reduction in comparison to photon techniques. Among photon techniques, VMAT is a preferred choice for most of out-of-field organs and especially for the thyroid, while doses for eyes, breasts and lungs, are lower for 3D-CRT. For organs outside the field edge, a simple analytical model can be helpful for clinicians involved in treatment planning using photon RT but also for retrospective data analysis for cancer risk estimates and epidemiology in general. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Marija Majer
- Ruđer Bošković Institute, Zagreb, 10000, Croatia
| | - Iva Ambrožová
- Nuclear Physics Institute of the CAS, Řež, CZ-250 68, Czech Republic
| | - Marie Davídková
- Nuclear Physics Institute of the CAS, Řež, CZ-250 68, Czech Republic
| | | | - Mladen Kasabašić
- Osijek University Hospital, Osijek, 31000, Croatia.,Faculty of Medicine Osijek, J.J. Strossmayer University of Osijek, Osijek, 31000, Croatia
| | | | - Renata Kopeć
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, 31-342, Poland
| | - Dawid Krzempek
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, 31-342, Poland
| | - Katarzyna Krzempek
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, 31-342, Poland
| | | | - Natalia Mojżeszek
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, 31-342, Poland
| | - Ivan Veršić
- Department of Physics, Faculty of Science, University of Zagreb, Zagreb, 10000, Croatia
| | - Liliana Stolarczyk
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, 31-342, Poland.,Danish Center for Particle Therapy, Aarhus, Denmark
| | - Roger M Harrison
- University of Newcastle, Newcastle upon Tyne, NE2 4HH, United Kingdom
| | - Paweł Olko
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, 31-342, Poland
| |
Collapse
|
7
|
Yeom YS, Griffin KT, Mille MM, Lee C, O’Reilly S, Dong L, Jung JW, Lee C. Fetal dose from proton pencil beam scanning craniospinal irradiation during pregnancy: a Monte Carlo study. Phys Med Biol 2022; 67:10.1088/1361-6560/ac4b38. [PMID: 35026741 PMCID: PMC9890509 DOI: 10.1088/1361-6560/ac4b38] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Accepted: 01/13/2022] [Indexed: 02/03/2023]
Abstract
Objective. We conducted a Monte Carlo study to comprehensively investigate the fetal dose resulting from proton pencil beam scanning (PBS) craniospinal irradiation (CSI) during pregnancy.Approach. The gestational-age dependent pregnant phantom series developed at the University of Florida (UF) were converted into DICOM-RT format (CT images and structures) and imported into a treatment planning system (TPS) (Eclipse v15.6) commissioned to a IBA PBS nozzle. A proton PBS CSI plan (prescribed dose: 36 Gy) was created on the phantoms. The TOPAS MC code was used to simulate the proton PBS CSI on the phantoms, for which MC beam properties at the nozzle exit (spot size, spot divergence, mean energy, and energy spread) were matched to IBA PBS nozzle beam measurement data. We calculated mean absorbed doses for 28 organs and tissues and whole body of the fetus at eight gestational ages (8, 10, 15, 20, 25, 30, 35, and 38 weeks). For contextual purposes, the fetal organ/tissue doses from the treatment planning CT scan of the mother's head and torso were estimated using the National Cancer Institute dosimetry system for CT (NCICT, Version 3) considering a low-dose CT protocol (CTDIvol: 8.97 mGy).Main results. The majority of the fetal organ/tissue doses from the proton PBS CSI treatment fell within a range of 3-6 mGy. The fetal organ/tissue doses for the 38 week phantom showed the largest variation with the doses ranging from 2.9 mGy (adrenals) to 8.2 mGy (eye lenses) while the smallest variation ranging from 3.2 mGy (oesophagus) to 4.4 mGy (brain) was observed for the doses for the 20 week phantom. The fetal whole-body dose ranged from 3.7 mGy (25 weeks) to 5.8 mGy (8 weeks). Most of the fetal doses from the planning CT scan fell within a range of 7-13 mGy, approximately 2-to-9 times lower than the fetal dose equivalents of the proton PBS CSI treatment (assuming a quality factor of 7).Significance. The fetal organ/tissue doses observed in the present work will be useful for one of the first clinically informative predictions on the magnitude of fetal dose during proton PBS CSI during pregnancy.
Collapse
Affiliation(s)
- Yeon Soo Yeom
- Department of Radiation Convergence Engineering, Yonsei University, Wonju, Gangwon 26493, Korea
| | - Keith T. Griffin
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA
| | - Matthew M. Mille
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA
| | - Choonik Lee
- Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
| | - Shannon O’Reilly
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Lei Dong
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Jae Won Jung
- Department of Physics, East Carolina University, Greenville, NC 27858, USA
| | - Choonsik Lee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, USA
| |
Collapse
|
8
|
Leite AMM, Ronga MG, Giorgi M, Ristic Y, Perrot Y, Trompier F, Prezado Y, Créhange G, De Marzi L. Secondary neutron dose contribution from pencil beam scanning, scattered and spatially fractionated proton therapy. Phys Med Biol 2021; 66. [PMID: 34673555 DOI: 10.1088/1361-6560/ac3209] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Accepted: 10/21/2021] [Indexed: 11/11/2022]
Abstract
The Orsay Proton therapy Center (ICPO) has a long history of intracranial radiotherapy using both double scattering (DS) and pencil beam scanning (PBS) techniques, and is actively investigating a promising modality of spatially fractionated radiotherapy using proton minibeams (pMBRT). This work provides a comprehensive comparison of the organ-specific secondary neutron dose due to each of these treatment modalities, assessed using Monte Carlo (MC) algorithms and measurements. A MC model of a universal nozzle was benchmarked by comparing the neutron ambient dose equivalent,H*(10), in the gantry room with measurements obtained using a WENDI-II counter. The secondary neutron dose was evaluated for clinically relevant intracranial treatments of patients of different ages, in which secondary neutron doses were scored in anthropomorphic phantoms merged with the patients' images. The MC calculatedH*(10) values showed a reasonable agreement with the measurements and followed the expected tendency, in which PBS yields the lowest dose, followed by pMBRT and DS. Our results for intracranial treatments show that pMBRT yielded a higher secondary neutron dose for organs closer to the target volume, while organs situated furthest from the target volume received a greater quantity of neutrons from the passive scattering beam line. To the best of our knowledge, this is the first study to compare MC secondary neutron dose estimates in clinical treatments between these various proton therapy modalities and to realistically quantify the secondary neutron dose contribution of clinical pMBRT treatments. The method established in this study will enable epidemiological studies of the long-term effects of intracranial treatments at ICPO, notably radiation-induced second malignancies.
Collapse
Affiliation(s)
- A M M Leite
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France.,Institut Curie, PSL Research University, University Paris Saclay, Inserm U 1021- CNRS UMR 3347, F-91898 Orsay, France
| | - M G Ronga
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France
| | - M Giorgi
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France
| | - Y Ristic
- Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie, Laboratoire de Dosimétrie des Rayonnements Ionisants, F-92262 Fontenay-aux-Roses Cedex, France
| | - Y Perrot
- Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie, Laboratoire de Dosimétrie des Rayonnements Ionisants, F-92262 Fontenay-aux-Roses Cedex, France
| | - F Trompier
- Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie, Laboratoire de Dosimétrie des Rayonnements Ionisants, F-92262 Fontenay-aux-Roses Cedex, France
| | - Y Prezado
- Institut Curie, PSL Research University, University Paris Saclay, Inserm U 1021- CNRS UMR 3347, F-91898 Orsay, France
| | - G Créhange
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France
| | - L De Marzi
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France.,Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, F-91898 Orsay, France
| |
Collapse
|
9
|
Thorne MC. An excess of riches: the Bernard Wheatley Award for 2020. JOURNAL OF RADIOLOGICAL PROTECTION : OFFICIAL JOURNAL OF THE SOCIETY FOR RADIOLOGICAL PROTECTION 2021; 41:E14-E19. [PMID: 34486530 DOI: 10.1088/1361-6498/ac023e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Accepted: 05/17/2021] [Indexed: 06/13/2023]
Affiliation(s)
- M C Thorne
- Quarry Cottage, Hamsterley, Bishop Auckland, County Durham DL13 3NJ, United Kingdom
| |
Collapse
|
10
|
Taylor S, Lim P, Ahmad R, Alhadi A, Harris W, Rompokos V, D'Souza D, Gaze M, Gains J, Veiga C. Risk of radiation-induced second malignant neoplasms from photon and proton radiotherapy in paediatric abdominal neuroblastoma. Phys Imaging Radiat Oncol 2021; 19:45-52. [PMID: 34307918 PMCID: PMC8295851 DOI: 10.1016/j.phro.2021.06.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 05/28/2021] [Accepted: 06/18/2021] [Indexed: 12/02/2022] Open
Abstract
BACKGROUND AND PURPOSE State-of-the-art radiotherapy modalities have the potential of reducing late effects of treatment in childhood cancer survivors. Our aim was to investigate the carcinogenic risk associated with 3D conformal (photon) radiation (3D-CRT), intensity modulated arc therapy (IMAT) and pencil beam scanning proton therapy (PBS-PT) in the treatment of paediatric abdominal neuroblastoma. MATERIALS AND METHODS The risk of radiation-induced second malignant neoplasm (SMN) was estimated using the concept of organ equivalent dose (OED) for eleven organs (lungs, rectum, colon, stomach, small intestine, liver, bladder, skin, central nervous system (CNS), bone, and soft tissues). The risk ratio (RR) between radiotherapy modalities and lifetime absolute risks (LAR) were reported for twenty abdominal neuroblastoma patients (median, 4y; range, 1-9y) historically treated with 3D-CRT that were also retrospectively replanned for IMAT and PBS-PT. RESULTS The risk of SMN due to primary radiation was reduced in PBS-PT against 3D-CRT and IMAT for most patients and organs. The RR across all organs ranged from 0.38 ± 0.22 (bladder) to 0.98 ± 0.04 (CNS) between PBS-PT and IMAT, and 0.12 ± 0.06 (rectum and bladder) to 1.06 ± 0.43 (bone) between PBS-PT and 3D-CRT. The LAR for most organs was within 0.01-1% (except the colon) with a cumulative risk of 21 ± 13%, 35 ± 14% and 35 ± 16% for PBS-PT, IMAT and 3D-CRT, respectively. CONCLUSIONS PBS-PT was associated with the lowest risk of radiation-induced SMN compared to IMAT and 3D-CRT in abdominal neuroblastoma treatment. Other clinical endpoints and plan robustness should also be considered for optimal plan selection.
Collapse
Affiliation(s)
- Sophie Taylor
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| | - Pei Lim
- Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Reem Ahmad
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| | - Ammar Alhadi
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| | - William Harris
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| | - Vasilis Rompokos
- Radiotherapy Physics Services, University College London Hospitals NHS Foundation Trust, London, UK
| | - Derek D'Souza
- Radiotherapy Physics Services, University College London Hospitals NHS Foundation Trust, London, UK
| | - Mark Gaze
- Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Jennifer Gains
- Department of Oncology, University College London Hospitals NHS Foundation Trust, London, UK
| | - Catarina Veiga
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK
| |
Collapse
|
11
|
Yeom YS, Griffin K, Mille M, Jung JW, Lee C, Lee C. A dose voxel kernel method for rapid reconstruction of out-of-field neutron dose of patients in pencil beam scanning (PBS) proton therapy. Phys Med Biol 2020; 65:175015. [PMID: 32726766 PMCID: PMC10182832 DOI: 10.1088/1361-6560/abaa5f] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Monte Carlo (MC) radiation transport methods are used for dose calculation as 'gold standard.' However, the method is computationally time-consuming and thus impractical for normal tissue dose reconstructions for the large number of proton therapy patients required for epidemiologic investigations of late health effects. In the present study, we developed a new dose calculation method for the rapid reconstruction of out-of-field neutron dose to patients undergoing pencil beam scanning (PBS) proton therapy. The new dose calculation method is based on neutron dose voxel kernels (DVKs) generated by MC simulations of a proton pencil beam irradiating a water phantom (60 × 60 × 300 cm3), which was conducted using a MC proton therapy simulation code, TOPAS. The DVKs were generated for 19 beam energies (from 70 to 250 MeV with the 10 MeV interval) and three range shifter thicknesses (1, 3, and 5 cm). An in-house program was written in C++ to superimpose the DVKs onto a patient CT images according to proton beam characteristics (energy, position, and direction) available in treatment plans. The DVK dose calculation method was tested by calculating organ/tissue-specific neutron doses of 1- and 5-year-old whole-body computational phantoms where intracranial and craniospinal irradiations were simulated. The DVK-based doses generally showed reasonable agreement with those calculated by direct MC simulations with a detailed PBS model that were previously published, with differences mostly less than 30% and 10% for the intracranial and craniospinal irradiations, respectively. The computation time of the DVK method for one patient ranged from 1 to 30 min on a single CPU core of a personal computer, demonstrating significant improvement over the direct MC dose calculation requiring several days on high-performance computing servers. Our DVK-based dose calculation method will be useful when dosimetry is needed for the large number of patients such as for epidemiologic or clinical research.
Collapse
Affiliation(s)
- Yeon Soo Yeom
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20850, United States of America
| | | | | | | | | | | |
Collapse
|